The Society of Interventional Oncology NCCN Committee spearheaded an effort in 2019 to provide input into the 2020 update of Kidney Cancer NCCN guidelines. SIO brought our RCC task force together and helped us through the specifics of the NCCN submission process. The 2020 NCCN guidelines for kidney cancer have recently been released and changes were made to the guidelines that give more prominence to ablation as a treatment option for T1a renal cell carcinoma. The specific recommendations from the SIO were implemented in the algorithm for treatment and in the Principles of Surgery section of the guidelines. It is critical that national guidelines reflect the latest developments in research and clinical practice. Updating the NCCN guidelines in this manner will help patients get the optimal treatment. It will also assist interventional oncologists at the local and national level. Locally, it can help IOs during discussions regarding treatment options at individual tumor boards. At the national level, updating the role of ablation in the NCCN guidelines could assist with issues such as funding of clinical trials, procedural reimbursement coverage and industry investment in R & D.
The SIO Kidney Task Force was chaired by Bill Stavropoulos from the University of Pennsylvania in collaboration with Ron Arellano from MGH and Tom Atwell from Mayo Clinic. SIO also submitted comments to the Breast, Colon, Liver, NET , and Adult Cancer Pain Panels and will provide updates as they become available.
For more information on the work of SIO's NCCN Committee, visit: http://www.sio-central.org/page/nccn